Markets
EBS

DBV Technologies Reveals Positive Data on Viaskin Peanut

An image of a globe with financial data surrounding it
Credit: Shutterstock photo

DBV TechnologiesDBVT announced top-line results from the OLFUS study on Viaskin Peanut for the treatment of patients with peanut allergy. The ongoing, open-label, follow-up study to VIPES (Viaskin Peanut's Efficacy and Safety) demonstrated long-term safety and efficacy of the candidate in the first 12 months.

Data showed an increase in the number of patients benefiting from the additional 12-month treatment with Viaskin Peanut to 70% in OLFUS from 50% in VIPES, with 80% children responding to therapy after 24 months.

The company expects to initiate a phase III (PEPITES) study on Viaskin Peanut in children aged between 4 years - 11 years in the fourth quarter of 2015.

We note that Viaskin Peanut has Fast Track and Breakthrough Therapy designation in the U.S. for the treatment of peanut allergy in children.

Meanwhile, the company is also working on developing Viaskin Milk to treat children allergic to milk. In Jul, 2015, the FDA accepted an investigator-sponsored Investigational New Drug application for a phase IIa proof-of-concept study on Viaskin Milk for the treatment of milk-induced eosinophilic esophagitis (EoE) in children. The company expects to initiate the SMILEE (Study Efficacy and Safety of the Viaskin Milk in milk-induced Eosinophilic Esophagitis) study in children (age 4 years -17 years) suffering from milk-induced EoE later this year.

Apart from the ongoing studies on Viaskin Milk and Viaskin Peanut, the company has one experimental program on Viaskin Egg.

DBV Technologies carries a Zacks Rank #2 (Buy). Other favorably ranked stocks in the health care sector include Emergent BioSolutions, Inc. EBS , Nexvet Biopharma Public Limited Company NVET and Regeneron Pharmaceuticals, Inc. REGN , each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

REGENERON PHARM (REGN): Free Stock Analysis Report

EMERGENT BIOSOL (EBS): Free Stock Analysis Report

DBV TECH SA-ADR (DBVT): Free Stock Analysis Report

NEXVET BIOPHARM (NVET): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

EBS REGN DBVT

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More